ArticleJournal of hepatocellular carcinoma2026
HAIC Combined with Lenvatinib and Pembrolizumab for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: The optimal treatment strategy for unresectable hepatocellular carcinoma (uHCC) remains under active investigation. Hepatic arterial infusion chemotherapy (HAIC) has shown promising outcomes, particularly among patients with high intrahepatic tumor burden. We assessed outcomes and tolerability of HAIC combined with lenvatinib and pembrolizumab (HAIC+L+P) as initial treatment for uHCC. Methods: We retrospectively identified consecutive, treatment-naïve patients with uHCC (BCLC stage B/C) treated with HAIC+L+P at a single center from January 2019 to January 2024. Tumor responses were evaluated using RECIST 1.1 and mRECIST. Overall survival (OS), progression-free survival (PFS), and treatment-related adverse events (AEs) were analyzed. Results: Sixty-six patients were analyzed, of whom 81.8% had BCLC stage C disease, 68.2% had vascular invasion, and 45.5% had extrahepatic metastasis. The median PFS was 9.63 months (95% CI, 6.59-12.68), and the median OS was 27.50 months (95% CI, 18.17-36.83). The ORR was 47.0% according to RECIST 1.1 and 66.7% according to mRECIST, with a DCR of 90.9% by both criteria. Six patients (9.1%) underwent curative-intent surgical resection during treatment. All AEs were controllable and no treatment-related deaths were recorded. Conclusion: HAIC combined with lenvatinib and pembrolizumab was associated with encouraging antitumor activity and a manageable safety profile in this real-world cohort. These findings should be considered hypothesis-generating and warrant validation in prospective controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.